BioLineRx (NASDAQ:BLRX) Price Target Lowered to $9.00 at HC Wainwright

BioLineRx (NASDAQ:BLRX) had its price target decreased by investment analysts at HC Wainwright from $21.00 to $9.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock.

Separately, StockNews.com started coverage on BioLineRx in a research note on Sunday. They set a “hold” rating on the stock.

BioLineRx Trading Down 5.0 %

NASDAQ:BLRX traded down $0.01 during trading hours on Monday, hitting $0.26. The company had a trading volume of 5,032,159 shares, compared to its average volume of 442,809. The company has a current ratio of 1.61, a quick ratio of 1.49 and a debt-to-equity ratio of 1.34. The company has a 50-day moving average of $0.49 and a 200 day moving average of $0.61. The company has a market cap of $21.12 million, a P/E ratio of -0.62 and a beta of 1.48. BioLineRx has a 1 year low of $0.25 and a 1 year high of $1.89.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Atria Investments Inc increased its holdings in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares during the last quarter. PVG Asset Management Corp purchased a new position in BioLineRx during the 2nd quarter worth approximately $70,000. Finally, CVI Holdings LLC purchased a new position in BioLineRx during the 2nd quarter worth approximately $462,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.